Pharma News, 2022

Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it has terminat...

Denmark-based biotech company Bavarian Nordic announced Thursday that the upcoming Phase III trial for ABNCoV2, its COVID-19 booster candidate, has been redesigned to compete against Pfizer-BioNTec...

A survey of clinical research executives working in the cancer arena has found that nearly three quarters of them will include decentralised designs in trials due to start in the next 12 months. ...

As part of its ongoing divestment program, a deal worth $2.1 billion has been struck between Johnson & Johnson (J&J) and US private equity firm Platinum Equity over the sale of the company ...

The litany of failed trials of amyloid-targeting drugs for Alzheimer’s disease has added another verse, as Roche concedes that its crenezumab candidate was unable to slow cognitive decline in pat...

Biogen has terminated its asset purchase agreement with Karyopharm Therapeutics, putting a halt to the development of KPT-350 (BIIB100), which was being tested in Phase 1 as a treatment for amyotr...

Kintara Therapeutics (NASDAQ:KTRA) on Wednesday said that the U.S. FDA had granted a Fast Track designation to its therapeutic VAL-083 for the treatment of newly-diagnosed unmethylated glioblastom...

The FDA is faster to approve new oncology therapies compared with the European Medicines Agency (EMA); but that speed may have consequences.

Leading healthcare venture capital firm Third Rock Ventures announced a new fund Wednesday morning, Third Rock Ventures Fund VI, providing the company with $1.1 billion to invest in new life scienc...

Researchers at Oxford University have identified a gene linked to pain, opening possibilities to develop drugs or gene therapies to help treat patients who suffer from chronic pain. ...

The FDA approved Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis, a rare inherited disease caused by mu...

NRx Pharmaceuticals Inc. (NRXP) said that the U.S. Food and Drug Administration denied the breakthrough therapy designation request for Zyesami or aviptadil and emphasized its focus on the company'...